A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
7 Hills Pharma, LLC
National Institutes of Health Clinical Center (CC)
Pfizer
Centre Oscar Lambret
University of California, San Francisco
M.D. Anderson Cancer Center
Essen Biotech
Beth Israel Deaconess Medical Center
Merck Sharp & Dohme LLC
Takeda
Kidney Cancer Research Bureau
Second Life Therapeutics
NiKang Therapeutics, Inc.
Hadassah Medical Organization
Arsenal Biosciences, Inc.
A2 Biotherapeutics Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Sensei Biotherapeutics, Inc.
ModeX Therapeutics, An OPKO Health Company
Cancer Research UK
Memorial Sloan Kettering Cancer Center
Indiana University
Nimbus Therapeutics
Kidney Cancer Research Bureau
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sumitomo Pharma America, Inc.
Aravive, Inc.
Ludwig Institute for Cancer Research
City of Hope Medical Center
Kineta Inc.
Ludwig Institute for Cancer Research
Hoosier Cancer Research Network
SCRI Development Innovations, LLC
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Big Ten Cancer Research Consortium
Novartis
Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus
MedImmune LLC
Rexahn Pharmaceuticals, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
N.N. Petrov National Medical Research Center of Oncology
Fuda Cancer Hospital, Guangzhou
National Institutes of Health Clinical Center (CC)
University of Oxford
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
Amgen
University of Kansas Medical Center